^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Abstract 4325: A Phase II exploratory study to identify biomarkers prognostic of clinical response to regorafenib in patients with metastatic colorectal cancer who have failed first-line therapy

Published date:
05/15/2020
Excerpt:
Interestingly, CN gains targeting three genes, GPR52, PTGS2 and MYC, classified within the drug resistance gene category in the drug-interaction database (DGIdb), were associated with a shorter PFS (Kaplan Meier analysis). 
DOI:
10.1158/1538-7445.AM2020-4325
Trial ID: